Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708654 | 0.95 | HIF1A (0.38) | HIF1AEPAS1PRKAB2PRKAG1PRKAA2 | |
| Trifluoroacetic Acid SCHEMBL3678836 | 0.91 | SLC2A1 (0.44) | SLC2A1HIF1AEPAS1PRKAB2PRKAG1 | |
| Trifluoroacetic Acid SCHEMBL3147599 | 0.91 | SLC2A1 (0.44) | SLC2A1HIF1AEPAS1PRKAB2PRKAG1 | |
| Trifluoroacetic Acid SCHEMBL3678977 | 0.91 | GAA (0.44) | SLC2A1HIF1AEPAS1PRKAB2PRKAG1 | |
| Trifluoroacetic Acid SCHEMBL3678978 | 0.91 | GAA (0.44) | SLC2A1HIF1AEPAS1PRKAB2PRKAG1 | |
| Trifluoroacetic Acid SCHEMBL2573371 | 0.89 | HIF1A (0.47) | SLC2A1HIF1AEPAS1 | |
| Trifluoroacetic Acid SCHEMBL2573372 | 0.89 | HIF1A (0.47) | SLC2A1HIF1AEPAS1 | |
| Trifluoroacetic Acid SCHEMBL2567335 | 0.88 | ALDH1A1 (0.43) | SLC2A1HIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL2570177 | 0.87 | KMT2A (0.46) | FAAHGAA | |
| SCHEMBL2570172 | 0.87 | KMT2A (0.46) | FAAHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | SLC2A1 1130/4885HIF1A 655/4885EPAS1 1308/4885 |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | SLC2A1 1000/4885HIF1A 706/4885EPAS1 1456/4885 |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | MMP1, COL1A1, IDO1 | SLC2A1 1451/4885HIF1A 808/4885EPAS1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.